FDA Clearance Tracker · P220013-S022
TactiFlex Sensor Enabled Ablation Catheter
Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this decision)Source: openFDAMethods & limitations
Decided
May 28, 2026
Approved
Time to decision
253 days
Received Sep 17, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P220013-S022
- Device name
- TactiFlex Sensor Enabled Ablation Catheter
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Plymouth, MN
- Received
- Sep 17, 2025
- Decided
- May 28, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P220013
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
Approval for labeling changes that would allow for alternative imaging modalities, such as intracardiac echocardiography (ICE), to aid in the navigation and positioning of the TactiFlex, Sensor Enabled (SE) Ablation Catheter.
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.